Prescriptions for Pfizer's stop-smoking drug Chantix dropped 5 percent last week after the FDA called it "increasingly likely [1]" that there is a link between use of the drug and various neuro-psychiatric symptoms, including suicidal behavior. Report [2]
Links:
[1] http://www.fiercepharma.com/story/fda-chantix-may-pose-psych-risks/2008-02-04
[2] http://money.cnn.com/news/newsfeeds/articles/djf500/200802141448DOWJONESDJONLINE000992_FORTUNE5.htm